HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CHRM1
cholinergic receptor muscarinic 1
Chromosome 11 Β· 11q12.3
NCBI Gene: 1128Ensembl: ENSG00000168539.5HGNC: HGNC:1950UniProt: P11229
124PubMed Papers
20Diseases
56Drugs
1Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedReceptor
CLINICAL
FDA Approved Target
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein bindingpositive regulation of monoatomic ion transportchemical synaptic transmissiondendriteParkinson diseasechronic obstructive pulmonary diseasegastrointestinal diseasemyopia
✦AI Summary

CHR11 encodes a muscarinic acetylcholine receptor that functions as a G protein-coupled receptor mediating diverse cellular responses through phosphoinositide turnover and modulation of ion channels and adenylate cyclase. CHR11 operates across multiple physiological systems with distinct functional outcomes depending on tissue and context. In the nervous system, CHR11 plays critical roles in cognitive function and sleep regulation. CHR11 expression is significantly reduced in Alzheimer's disease brains compared to healthy controls, with regional, age, and sex-specific differences 1. CHR11 is essential for REM sleep regulation 2, and hippocampal CHR11-dependent cholinergic signaling is necessary for cognitive protection following anesthesia and surgery, operating through BDNF/TrkB pathway interactions 3. In schizophrenia, CHR11 activation as part of dual M1/M4 agonist therapy shows efficacy for symptom management with improved tolerability 4. In oncology, CHR11 shows opposing effects depending on tumor type. Midbrain cholinergic neurons promote diffuse midline glioma growth through CHR11/M3 signaling 5, whereas CHR11 activation suppresses pancreatic ductal adenocarcinoma progression by inhibiting MAPK/EGFR and PI3K/AKT pathways and reducing cancer stem cell populations 6. Endogenous DOPA inhibits melanoma by suppressing CHR11 signaling, making CHR11 antagonism a potential therapeutic strategy 7. CHR11 activation also demonstrates anti-fibrotic effects in metabolic dysfunction-associated steatohepatitis through inhibition of TRPM8 8.

Sources cited
1
CHRM1 expression is significantly reduced in Alzheimer's disease brains and shows regional, age, and sex-specific expression patterns
PMID: 36475335
2
CHRM1 (Gq-type muscarinic receptor) is essential for REM sleep regulation
PMID: 32009883
3
Hippocampal CHRM1 is required for cognitive protection against anesthesia/surgery-induced cognitive dysfunction and operates through BDNF/TrkB signaling
PMID: 39558340
4
CHRM1 activation as part of dual M1/M4 agonist therapy is effective for schizophrenia treatment with favorable tolerability profile
PMID: 40056428
5
Midbrain cholinergic neuronal activity promotes diffuse midline glioma growth through CHRM1 and CHRM3 signaling
PMID: 40541184
6
CHRM1 activation suppresses pancreatic ductal adenocarcinoma by inhibiting MAPK/EGFR and PI3K/AKT pathways and reducing cancer stem cell compartment
PMID: 30185628
7
Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling, and CHRM1 antagonism inhibits melanoma tumor growth
PMID: 36054350
8
CHRM1 activation demonstrates anti-fibrotic effects in metabolic dysfunction-associated steatohepatitis through inhibition of TRPM8 via Gq/11 and phospholipase C signaling
PMID: 39605182
Disease Associationsβ“˜20
Parkinson diseaseOpen Targets
0.66Moderate
chronic obstructive pulmonary diseaseOpen Targets
0.60Moderate
gastrointestinal diseaseOpen Targets
0.58Moderate
myopiaOpen Targets
0.58Moderate
Peptic ulcerOpen Targets
0.58Moderate
asthmaOpen Targets
0.57Moderate
HyperhidrosisOpen Targets
0.55Moderate
MydriasisOpen Targets
0.55Moderate
allergic rhinitisOpen Targets
0.54Moderate
xerostomiaOpen Targets
0.54Moderate
motion sicknessOpen Targets
0.54Moderate
seasonal allergic rhinitisOpen Targets
0.53Moderate
chronic bronchitisOpen Targets
0.53Moderate
emphysemaOpen Targets
0.53Moderate
NauseaOpen Targets
0.53Moderate
peptic ulcer diseaseOpen Targets
0.53Moderate
glaucomaOpen Targets
0.52Moderate
open-angle glaucomaOpen Targets
0.52Moderate
Nausea and vomitingOpen Targets
0.51Moderate
irritable bowel syndromeOpen Targets
0.50Moderate
Pathogenic Variants1
NM_000738.3(CHRM1):c.1274T>C (p.Phe425Ser)Likely pathogenic
See cases|CHRM1-related neurodevelopmental disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 425
View on ClinVar β†—
Drug Targets56
AFACIFENACINPhase II
Muscarinic acetylcholine receptor antagonist
overactive bladder
ANISOTROPINE METHYLBROMIDEApproved
Muscarinic acetylcholine receptor M1 antagonist
Peptic ulcer
ASM-024Phase II
Muscarinic acetylcholine receptor M1 antagonist
asthma
ATROPINEApproved
Muscarinic acetylcholine receptor M2 antagonist
Mydriasis
ATROPINE SULFATEApproved
Muscarinic acetylcholine receptor M2 antagonist
Mydriasis
BENZTROPINEApproved
Muscarinic acetylcholine receptor M1 antagonist
Parkinson disease
BENZTROPINE MESYLATEApproved
Muscarinic acetylcholine receptor M1 antagonist
Parkinson disease
BIPERIDENApproved
Muscarinic acetylcholine receptor M1 antagonist
Parkinson disease
BIPERIDEN HYDROCHLORIDEUNKNOWN
Muscarinic acetylcholine receptor M1 antagonist
BIPERIDEN LACTATEPhase III
Muscarinic acetylcholine receptor M1 antagonist
brain injury
CEVIMELINEApproved
Muscarinic acetylcholine receptor M1 agonist
Sjogren syndrome
CEVIMELINE HYDROCHLORIDEApproved
Muscarinic acetylcholine receptor M1 agonist
xerostomia
CLIDINIUMApproved
Muscarinic acetylcholine receptor M1 antagonist
CLIDINIUM BROMIDEApproved
Muscarinic acetylcholine receptor M1 antagonist
gastrointestinal disease
CYCRIMINEApproved
Muscarinic acetylcholine receptor M1 antagonist
Parkinson disease
DAROTROPIUMPhase II
Muscarinic acetylcholine receptor antagonist
chronic obstructive pulmonary disease
DAROTROPIUM BROMIDEPhase II
Muscarinic acetylcholine receptor antagonist
chronic obstructive pulmonary disease
DICYCLOMINEApproved
Muscarinic acetylcholine receptor M1 antagonist
gastrointestinal disease
DICYCLOMINE HYDROCHLORIDEApproved
Muscarinic acetylcholine receptor M1 antagonist
irritable bowel syndrome
DIPHEMANILApproved
Muscarinic acetylcholine receptor M3 antagonist
gastrointestinal disease
DIPHEMANIL METHYLSULFATEApproved
Muscarinic acetylcholine receptor M3 antagonist
Peptic ulcer
DIPHENIDOLApproved
Muscarinic acetylcholine receptor M1 antagonist
Nausea
ETHOPROPAZINEApproved
Muscarinic acetylcholine receptor M1 antagonist
Parkinson disease
GLYCOPYRRONIUMApproved
Muscarinic acetylcholine receptor M1 antagonist
chronic obstructive pulmonary disease
GLYCOPYRRONIUM BROMIDEApproved
Muscarinic acetylcholine receptor M1 antagonist
GLYCOPYRRONIUM TOSYLATEApproved
Muscarinic acetylcholine receptor inhibitor
peptic ulcer disease
HEXOCYCLIUMApproved
Muscarinic acetylcholine receptor M1 antagonist
gastrointestinal disease
ISOPROPAMIDEApproved
Muscarinic acetylcholine receptor M1 antagonist
gastrointestinal disease
ISOPROPAMIDE IODIDEApproved
Muscarinic acetylcholine receptor M1 antagonist
allergic rhinitis
MEPENZOLATEApproved
Muscarinic acetylcholine receptor M1 antagonist
gastrointestinal disease
METHIXENEApproved
Muscarinic acetylcholine receptor M1 antagonist
Parkinson disease
METHIXENE HYDROCHLORIDEApproved
Muscarinic acetylcholine receptor M1 antagonist
Parkinson disease
METHSCOPOLAMINEApproved
Muscarinic acetylcholine receptor M1 antagonist
gastrointestinal disease
METHSCOPOLAMINE BROMIDEApproved
Muscarinic acetylcholine receptor M1 antagonist
Nausea and vomiting
MINAPRINEApproved
Dopamine D1 and D2 receptor agonist
depressive disorder
MINAPRINE HYDROCHLORIDEUNKNOWN
Dopamine D1 and D2 receptor agonist
MK-7622Phase II
Muscarinic acetylcholine receptor M1 positive allosteric modulator
Alzheimer disease
OXYPHENCYCLIMINEApproved
Muscarinic acetylcholine receptor M1 antagonist
gastrointestinal disease
OXYPHENONIUMApproved
Muscarinic acetylcholine receptor M3 antagonist
gastrointestinal disease
PILOCARPINEApproved
Muscarinic acetylcholine receptor M1 agonist
xerostomia
PILOCARPINE HYDROCHLORIDEPhase III
Muscarinic acetylcholine receptor M1 agonist
PIRENZEPINEApproved
Muscarinic acetylcholine receptor M1 antagonist
gastroesophageal reflux disease
PROCYCLIDINEApproved
Muscarinic acetylcholine receptor M1 antagonist
Parkinson disease
PROPANTHELINEApproved
Muscarinic acetylcholine receptor M1 antagonist
gastrointestinal disease
PROPANTHELINE BROMIDEApproved
Muscarinic acetylcholine receptor M1 antagonist
peptic ulcer disease
SCOPOLAMINEApproved
Muscarinic acetylcholine receptor M1 antagonist
post operative nausea and vomiting
SOFPIRONIUM BROMIDEApproved
Muscarinic acetylcholine receptor inhibitor
TAK-071Phase II
Muscarinic acetylcholine receptor M1 positive allosteric modulator
Parkinson disease
TALSACLIDINEPhase II/III
Muscarinic acetylcholine receptor M1 agonist
Alzheimer disease
TERODILINEApproved
Muscarinic acetylcholine receptor antagonist
Urinary incontinence
TERODILINE HYDROCHLORIDEUNKNOWN
Muscarinic acetylcholine receptor antagonist
TRIDIHEXETHYLApproved
Muscarinic acetylcholine receptor M1 antagonist
gastrointestinal disease
TRIHEXYPHENIDYLApproved
Muscarinic acetylcholine receptor M1 antagonist
Dystonia
TRIHEXYPHENIDYL HYDROCHLORIDEEARLY_PHASE_1
Muscarinic acetylcholine receptor M1 antagonist
XANOMELINEPhase III
Muscarinic acetylcholine receptor M1 agonist
XANOMELINE TARTRATEPhase II
Muscarinic acetylcholine receptor M1 agonist
Parkinson disease
Related Genes
LPAR1Protein interaction100%LPAR5Protein interaction99%LPAR3Protein interaction98%GNAQProtein interaction97%LPAR4Protein interaction97%PLCB3Protein interaction95%
Tissue Expression6 tissues
Brain
100%
Lung
7%
Bone Marrow
1%
Ovary
0%
Heart
0%
Liver
0%
Gene Interaction Network
Click a node to explore
CHRM1LPAR1LPAR5LPAR3GNAQLPAR4PLCB3
PROTEIN STRUCTURE
Preparing viewer…
PDB6ZFZ Β· 2.17 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.33Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.15 [0.08–0.33]
RankingsWhere CHRM1 stands among ~20K protein-coding genes
  • #3,789of 20,598
    Most Researched124 Β· top quartile
  • #45of 1,025
    FDA-Approved Drug Targets41 Β· top 5%
  • #4,822of 5,498
    Most Pathogenic Variants1
  • #1,334of 17,882
    Most Constrained (LOEUF)0.33 Β· top 10%
Genes detectedCHRM1
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Cholinergic neuronal activity promotes diffuse midline glioma growth through muscarinic signaling.
PMID: 40541184
Cell Β· 2025
1.00
2
Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness.
PMID: 30185628
Cancer Discov Β· 2018
0.90
3
Sex, Age, and Regional Differences in
PMID: 36475335
Curr Neuropharmacol Β· 2023
0.80
4
Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention.
PMID: 39605182
Adv Sci (Weinh) Β· 2025
0.70
5
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.
PMID: 40056428
Int J Neuropsychopharmacol Β· 2025
0.60